Resverlogix Corp. (RVXCF)

[noretreat]

Here's something: $1.44 to 10 bucks plus??

http://www.leeuwenhoeck.com/


Resverlogix (RVX.TO): Update Report 1 May
Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. In October 2015, Resverlogix initiated a Phase III clinical trial "BETonMACE" with apabetalone in high-risk CVD patients with type 2 diabetes mellitus and low HDL. Resverlogix has enrolled more than 1,400 of the planned 2,400 patients. We have increased our valuation based on an estimated higher pricing for apabetalone and expanded markets in high risk CKD patients such as ESRD. We feel that the company’s current total value should be CAD 1,300 million, or CAD 12.50 per share.